146 related articles for article (PubMed ID: 27760934)
1. [Neoadjuvant Chemotherapy Using S-1 for Pancreatic Cancer - Mid-Term Results].
Homma Y; Honda G; Sakamoto K; Kurata M; Honjo M; Hirata Y; Shinya S
Gan To Kagaku Ryoho; 2016 Oct; 43(10):1166-1170. PubMed ID: 27760934
[TBL] [Abstract][Full Text] [Related]
2. [A Case of R0 Resection of Locally Advanced Pancreatic Cancer Following Chemoradiation Therapy].
Miyahara Y; Okamura D; Nishida T; Shimizu H; Ohtsuka M; Kato A; Yoshitomi H; Furukawa K; Takayashiki T; Kuboki S; Takano S; Suzuki D; Sakai N; Kagawa S; Miyazaki M
Gan To Kagaku Ryoho; 2015 Nov; 42(12):2382-4. PubMed ID: 26805371
[TBL] [Abstract][Full Text] [Related]
3. A Prospective Phase II Trial of Neoadjuvant S-1 with Concurrent Hypofractionated Radiotherapy in Patients with Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma.
Okano K; Suto H; Oshima M; Maeda E; Yamamoto N; Kakinoki K; Kamada H; Masaki T; Takahashi S; Shibata T; Suzuki Y
Ann Surg Oncol; 2017 Sep; 24(9):2777-2784. PubMed ID: 28608121
[TBL] [Abstract][Full Text] [Related]
4. Neo-adjuvant chemoradiation therapy using S-1 followed by surgical resection in patients with pancreatic cancer.
Satoi S; Toyokawa H; Yanagimoto H; Yamamoto T; Kamata M; Ohe C; Sakaida N; Uemura Y; Kitade H; Tanigawa N; Inoue K; Matsui Y; Kwon AH
J Gastrointest Surg; 2012 Apr; 16(4):784-92. PubMed ID: 22160780
[TBL] [Abstract][Full Text] [Related]
5. Immunological impact of neoadjuvant chemoradiotherapy in patients with borderline resectable pancreatic ductal adenocarcinoma.
Homma Y; Taniguchi K; Murakami T; Nakagawa K; Nakazawa M; Matsuyama R; Mori R; Takeda K; Ueda M; Ichikawa Y; Tanaka K; Endo I
Ann Surg Oncol; 2014 Feb; 21(2):670-6. PubMed ID: 24310792
[TBL] [Abstract][Full Text] [Related]
6. A phase II trial of neoadjuvant chemoradiotherapy with intensity-modulated radiotherapy combined with gemcitabine and S-1 for borderline-resectable pancreatic cancer with arterial involvement.
Nagakawa Y; Hosokawa Y; Nakayama H; Sahara Y; Takishita C; Nakajima T; Hijikata Y; Kasuya K; Katsumata K; Tokuuye K; Tsuchida A
Cancer Chemother Pharmacol; 2017 May; 79(5):951-957. PubMed ID: 28378027
[TBL] [Abstract][Full Text] [Related]
7. [A Case of Pancreatic Head Cancer Showing Pathological Complete Response to Neoadjuvant Chemoradiation Therapy].
Nakama Y; Kawahara R; Nomura Y; Muroya D; Arai S; Ishikawa H; Yasunaga M; Horiuchi H; Akagi Y; Tanaka H; Yasumoto M; Okabe Y; Torimura T; Naito Y; Okuda K
Gan To Kagaku Ryoho; 2015 Nov; 42(12):2376-8. PubMed ID: 26805369
[TBL] [Abstract][Full Text] [Related]
8. [The Efficacy of Neoadjuvant Chemoradiation Therapy for Borderline Resectable Pancreatic Cancer].
Sano T; Takano K; Chiba N; Tomita K; Ozawa Y; Hikita K; Shimazu M; Kawachi S
Gan To Kagaku Ryoho; 2015 Nov; 42(12):1488-90. PubMed ID: 26805072
[TBL] [Abstract][Full Text] [Related]
9. Combined Analyses of hENT1, TS, and DPD Predict Outcomes of Borderline-resectable Pancreatic Cancer.
Yabushita Y; Mori R; Taniguchi K; Matsuyama R; Kumamoto T; Sakamaki K; Kubota K; Endo I
Anticancer Res; 2017 May; 37(5):2465-2476. PubMed ID: 28476815
[TBL] [Abstract][Full Text] [Related]
10. Clinical outcomes of pancreatic ductal adenocarcinoma resection following neoadjuvant chemoradiation therapy vs. chemotherapy.
Satoi S; Yanagimoto H; Yamamoto T; Ohe C; Miyasaka C; Uemura Y; Hirooka S; Yamaki S; Ryota H; Michiura T; Inoue K; Matsui Y; Tanigawa N; Kon M
Surg Today; 2017 Jan; 47(1):84-91. PubMed ID: 27262676
[TBL] [Abstract][Full Text] [Related]
11. Pilot feasibility study of neoadjuvant chemoradiotherapy with S-1 in patients with locally advanced gastric cancer featuring adjacent tissue invasion or JGCA bulky N2 lymph node metastases.
Inoue T; Yachida S; Usuki H; Kimura T; Hagiike M; Okano K; Suzuki Y
Ann Surg Oncol; 2012 Sep; 19(9):2937-45. PubMed ID: 22466666
[TBL] [Abstract][Full Text] [Related]
12. Outcomes of neoadjuvant gemcitabine plus S-1 and radiation therapy for borderline resectable pancreatic cancer.
Yabushita Y; Matsuyama R; Miyake K; Homma Y; Kumamoto T; Misumi T; Hata M; Yamanaka S; Fujii S; Endo I
J Hepatobiliary Pancreat Sci; 2023 Apr; 30(4):493-502. PubMed ID: 36178433
[TBL] [Abstract][Full Text] [Related]
13. S-1 vs. gemcitabine as an adjuvant therapy after surgical resection for ductal adenocarcinoma of the pancreas.
Okabayashi T; Shima Y; Iwata J; Morita S; Sumiyoshi T; Kozuki A; Tokumaru T; Iiyama T; Kosaki T; Kobayashi M; Hanazaki K
World J Surg; 2014 Nov; 38(11):2986-93. PubMed ID: 25104544
[TBL] [Abstract][Full Text] [Related]
14. Clinical benefits of neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreatic head: an observational study using inverse probability of treatment weighting.
Fujii T; Satoi S; Yamada S; Murotani K; Yanagimoto H; Takami H; Yamamoto T; Kanda M; Yamaki S; Hirooka S; Kon M; Kodera Y
J Gastroenterol; 2017 Jan; 52(1):81-93. PubMed ID: 27169844
[TBL] [Abstract][Full Text] [Related]
15. [Preoperative chemoradiotherapy with S-1 for advanced low rectal cancer].
Kitani K; Okajima K; Sato K; Isono S; Kimura H; Ikeda M; Inoue K; Iwama M; Tsujie M; Nakayama T; Fujiwara Y; Murata M; Yukawa M; Ota Y; Inoue M
Gan To Kagaku Ryoho; 2011 Nov; 38(12):2122-4. PubMed ID: 22202303
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of stereotactic body radiation therapy combined with S-1 simultaneously followed by sequential S-1 as an initial treatment for locally advanced pancreatic cancer (SILAPANC) trial: study design and rationale of a phase II clinical trial.
Zhu X; Ju X; Cao F; Fang F; Qing S; Shen Y; Jia Z; Cao Y; Zhang H
BMJ Open; 2016 Dec; 6(12):e013220. PubMed ID: 27909037
[TBL] [Abstract][Full Text] [Related]
17. Prognostic impact of normalization of serum tumor markers following neoadjuvant chemotherapy in patients with borderline resectable pancreatic carcinoma with arterial contact.
Murakami Y; Uemura K; Sudo T; Hashimoto Y; Kondo N; Nakagawa N; Okada K; Takahashi S; Sueda T
Cancer Chemother Pharmacol; 2017 Apr; 79(4):801-811. PubMed ID: 28314992
[TBL] [Abstract][Full Text] [Related]
18. [Examination of resectable and borderline pancreatic cancer treated with neoadjuvant chemoradiation therapy].
Mataki Y; Shinchi H; Maemura K; Kurahara H; Kawasaki Y; Desaki R; Ueno S; Sakoda M; Iino S; Higashi M; Takao S; Natsugoe S
Gan To Kagaku Ryoho; 2013 Nov; 40(12):1637-40. PubMed ID: 24393873
[TBL] [Abstract][Full Text] [Related]
19. [A Case of Curatively Resected Locally Recurrent Rectal Mucinous Adenocarcinoma Followed by Preoperative Chemoradiotherapy].
Sato K; Karasawa H; Kajiwara T; Suzuki H; Kohyama A; Watanabe K; Ohnuma S; Ishida T; Kamei T; Naitoh T; Unno M
Gan To Kagaku Ryoho; 2019 Dec; 46(13):2440-2442. PubMed ID: 32156958
[TBL] [Abstract][Full Text] [Related]
20. Optimal indication of neoadjuvant chemoradiotherapy for pancreatic cancer.
Sho M; Akahori T; Tanaka T; Kinoshita S; Nagai M; Nishiwada S; Tamamoto T; Nishiofuku H; Ohbayashi C; Hasegawa M; Kichikawa K; Nakajima Y
Langenbecks Arch Surg; 2015 May; 400(4):477-85. PubMed ID: 25929828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
